We can tell by the sound of the motor vehicles passing by our window and the furious panting of the official mascots as they forage for breakfast ... obesity drug Zepbound, which were previously ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

These high-quality stocks continuously grow, maintain an edge over competitors, and make more money than the business needs.

Wake up with Breakfast news in your inbox every market ... guidance related to its blockbuster GLP-1 drugs, Mounjaro and Zepbound. For the fourth quarter, Lilly calls for revenue of $3.5 billion ...

Wake up with Breakfast news in your inbox every market day ... Lilly makes tirzepatide, sold under the name Zepbound for ...

Wake up with Breakfast news in your inbox every market ... Lilly makes tirzepatide, sold under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. These products have quickly ...

Wake up with Breakfast news in your inbox every market ... Lilly is the maker of GLP-1 treatments Mounjaro and Zepbound. For comparison’s sake, Mounjaro is essentially Lilly's answer to Ozempic ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Business: Breakfast isn't getting cheaper anytime ... Eli Lilly's weight-loss wonders. The Mounjaro and Zepbound producer hopes to close the gap with competitor Novo Nordisk's Ozempic — and ...

Weight loss drugs like Ozempic and Wegovy have dominated the diet discussion for the past few years. But this trend leaves many people wondering: What role does weight-loss surgery play in an ...